Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.

de Jong JJ, Stoop H, Nieboer D, Boormans JL, van Leenders GJLH.

Histopathology. 2018 Jul 12. doi: 10.1111/his.13710. [Epub ahead of print]

PMID:
30003574
2.

Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.

Kolijn K, Verhoef EI, Smid M, Böttcher R, Jenster GW, Debets R, van Leenders GJ.

Cancer Res. 2018 Jun 19. pii: canres.3752.2017. doi: 10.1158/0008-5472.CAN-17-3752. [Epub ahead of print]

PMID:
29921693
3.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
4.

Differences in recurrence and survival of extremity liposarcoma subtypes.

Vos M, Koseła-Paterczyk H, Rutkowski P, van Leenders GJLH, Normantowicz M, Lecyk A, Sleijfer S, Verhoef C, Grünhagen DJ.

Eur J Surg Oncol. 2018 Apr 6. pii: S0748-7983(18)30997-1. doi: 10.1016/j.ejso.2018.03.028. [Epub ahead of print]

PMID:
29673808
5.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238. [Epub ahead of print]

PMID:
29637669
6.

On cribriform prostate cancer.

Kweldam CF, van der Kwast T, van Leenders GJ.

Transl Androl Urol. 2018 Feb;7(1):145-154. doi: 10.21037/tau.2017.12.33. Review.

7.

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders GJLH, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):132-144. doi: 10.21037/tau.2017.12.29.

8.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6.

PMID:
29511030
9.

Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.

Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH.

BMC Cancer. 2018 Jan 2;18(1):8. doi: 10.1186/s12885-017-3976-z.

10.

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.

Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Histopathology. 2018 Apr;72(5):760-765. doi: 10.1111/his.13427. Epub 2018 Jan 14.

PMID:
29094386
11.

Raman spectroscopy for cancer detection and cancer surgery guidance: translation to the clinics.

Santos IP, Barroso EM, Bakker Schut TC, Caspers PJ, van Lanschot CGF, Choi DH, van der Kamp MF, Smits RWH, van Doorn R, Verdijk RM, Noordhoek Hegt V, von der Thüsen JH, van Deurzen CHM, Koppert LB, van Leenders GJLH, Ewing-Graham PC, van Doorn HC, Dirven CMF, Busstra MB, Hardillo J, Sewnaik A, Ten Hove I, Mast H, Monserez DA, Meeuwis C, Nijsten T, Wolvius EB, Baatenburg de Jong RJ, Puppels GJ, Koljenović S.

Analyst. 2017 Aug 21;142(17):3025-3047. doi: 10.1039/c7an00957g. Review.

PMID:
28726868
12.

Primary Cystic Lesions of the Retrorectal Space: MRI Evaluation and Clinical Assessment.

Dwarkasing RS, Verschuuren SI, van Leenders GJLH, Braun LMM, Krestin GP, Schouten WR.

AJR Am J Roentgenol. 2017 Oct;209(4):790-796. doi: 10.2214/AJR.16.17329. Epub 2017 Jul 13.

PMID:
28705066
13.

Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?

Alberts AR, Schoots IG, Bokhorst LP, Drost FH, van Leenders GJ, Krestin GP, Dwarkasing RS, Barentsz JO, Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514-6. doi: 10.1016/j.eururo.2017.06.019. [Epub ahead of print]

PMID:
28647216
14.

Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.

Bokhorst LP, Roobol MJ, Bangma CH, van Leenders GJ.

Prostate. 2017 Jul;77(10):1137-1143. doi: 10.1002/pros.23372. Epub 2017 May 24.

PMID:
28543353
15.

Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2017 Aug;30(8):1126-1132. doi: 10.1038/modpathol.2017.29. Epub 2017 May 19.

16.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
17.

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, Kelber J, Pelger RCM, Henry MD, Snaar-Jagalska E, van Leenders GJLH, Beimers L, Kloen P, Gray PC, van der Pluijm G, Kruithof-de Julio M.

Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.

18.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

PMID:
28267899
19.

Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.

Alberts AR, Bokhorst LP, Kweldam CF, Schoots IG, van der Kwast TH, van Leenders GJ, Roobol MJ.

Int J Urol. 2017 Apr;24(4):281-286. doi: 10.1111/iju.13294. Epub 2017 Feb 7.

20.

Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.

Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH.

Eur Urol. 2017 Jul;72(1):45-51. doi: 10.1016/j.eururo.2017.01.033. Epub 2017 Feb 2.

PMID:
28162815
21.

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.

Hoogland AM, Böttcher R, Verhoef E, Jenster G, van Leenders GJ.

Oncotarget. 2016 Jun 21;7(25):37846-37856. doi: 10.18632/oncotarget.9344.

22.

EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study.

Campos AK, Hoving HD, Rosati S, van Leenders GJ, de Jong IJ.

Int J Mol Sci. 2016 Sep 29;17(10). pii: E1650.

23.

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.

Böttcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R.

Oncotarget. 2016 Oct 25;7(43):70669-70684. doi: 10.18632/oncotarget.12204.

24.

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJ.

Eur J Cancer. 2016 Oct;66:26-33. doi: 10.1016/j.ejca.2016.07.012. Epub 2016 Aug 11.

PMID:
27522247
25.

Three-dimensional microscopic analysis of clinical prostate specimens.

van Royen ME, Verhoef EI, Kweldam CF, van Cappellen WA, Kremers GJ, Houtsmuller AB, van Leenders GJ.

Histopathology. 2016 Dec;69(6):985-992. doi: 10.1111/his.13022. Epub 2016 Sep 21.

PMID:
27353346
26.

MET expression during prostate cancer progression.

Verhoef EI, Kolijn K, De Herdt MJ, van der Steen B, Hoogland AM, Sleddens HF, Looijenga LH, van Leenders GJ.

Oncotarget. 2016 May 24;7(21):31029-36. doi: 10.18632/oncotarget.8829.

27.

Reninoma: A Rare Cause of Curable Hypertension and Hypokalemia.

Oei L, van den Meiracker AH, Oei EH, Moelker A, van Leenders GJ, Rikken B, Verhagen P, Clahsen-van Groningen MC, van der Wiel HE.

Am J Med. 2016 Aug;129(8):e131-2. doi: 10.1016/j.amjmed.2016.03.026. Epub 2016 Apr 18. No abstract available.

PMID:
27103051
28.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W.

Oncotarget. 2016 May 31;7(22):32916-24. doi: 10.18632/oncotarget.8767.

29.

Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.

Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Compérat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ.

Histopathology. 2016 Sep;69(3):441-9. doi: 10.1111/his.12976. Epub 2016 May 24.

30.

Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2016 Jun;29(6):630-6. doi: 10.1038/modpathol.2016.49. Epub 2016 Mar 4.

31.

Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.

De Herdt MJ, Willems SM, van der Steen B, Noorlag R, Verhoef EI, van Leenders GJ, van Es RJ, KoljenoviÄ S, Baatenburg de Jong RJ, Looijenga LH.

Oncotarget. 2016 Mar 15;7(11):13167-81. doi: 10.18632/oncotarget.7534.

32.

Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels.

Widagdo W, Raj VS, Schipper D, Kolijn K, van Leenders GJLH, Bosch BJ, Bensaid A, Segalés J, Baumgärtner W, Osterhaus ADME, Koopmans MP, van den Brand JMA, Haagmans BL.

J Virol. 2016 Apr 14;90(9):4838-4842. doi: 10.1128/JVI.02994-15. Print 2016 May.

33.

The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.

Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.

BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5. Review.

34.

Comparison of RNA extraction kits and histological stains for laser capture microdissected prostate tissue.

Kolijn K, van Leenders GJ.

BMC Res Notes. 2016 Jan 7;9:17. doi: 10.1186/s13104-015-1813-5.

35.

Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.

Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ.

Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.

PMID:
26651990
36.

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.

Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R.

Br J Cancer. 2015 Nov 17;113(10):1502-11. doi: 10.1038/bjc.2015.335.

37.

Androgen receptor profiling predicts prostate cancer outcome.

Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W.

EMBO Mol Med. 2015 Nov;7(11):1450-64. doi: 10.15252/emmm.201505424.

38.

The role of HOXC6 in prostate cancer development.

Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CF, van Leenders GJ, Verhaegh GW, Schalken JA.

Prostate. 2015 Dec;75(16):1868-76. doi: 10.1002/pros.23065. Epub 2015 Aug 27.

PMID:
26310814
39.

Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.

Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJLH, Jenster G, Aoyama H, Ferreira CV, Fuhler GM.

Eur Urol. 2016 Apr;69(4):710-719. doi: 10.1016/j.eururo.2015.06.040. Epub 2015 Jul 7.

PMID:
26159288
40.
41.

Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer.

Naipal KA, Raams A, Bruens ST, Brandsma I, Verkaik NS, Jaspers NG, Hoeijmakers JH, van Leenders GJ, Pothof J, Kanaar R, Boormans J, van Gent DC.

PLoS One. 2015 Apr 30;10(4):e0126029. doi: 10.1371/journal.pone.0126029. eCollection 2015.

42.

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.

Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G.

Oncotarget. 2015 Feb 28;6(6):4036-50.

43.

Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.

Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schröder FH, Bangma CH, Roobol MJ; ERSPC Rotterdam Study Group.

Eur Urol. 2015 Aug;68(2):179-82. doi: 10.1016/j.eururo.2014.10.008. Epub 2014 Oct 18.

PMID:
25457496
44.

Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.

van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH.

Mod Pathol. 2015 May;28(5):695-705. doi: 10.1038/modpathol.2014.154. Epub 2014 Nov 28.

45.

Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Beukers W, Kandimalla R, Masius RG, Vermeij M, Kranse R, van Leenders GJ, Zwarthoff EC.

Mod Pathol. 2015 Apr;28(4):515-22. doi: 10.1038/modpathol.2014.145. Epub 2014 Nov 14.

46.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

47.

Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.

Hoogland AM, Kweldam CF, van Leenders GJ.

Biomed Res Int. 2014;2014:341324. doi: 10.1155/2014/341324. Epub 2014 Aug 27. Review.

48.

Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.

Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ.

Mod Pathol. 2015 Mar;28(3):457-64. doi: 10.1038/modpathol.2014.116. Epub 2014 Sep 5.

49.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

50.

Disease-specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy.

Kweldam CF, Wildhagen MF, Bangma CH, van Leenders GJ.

BJU Int. 2015 Aug;116(2):230-5. doi: 10.1111/bju.12879. Epub 2015 Mar 7.

Supplemental Content

Loading ...
Support Center